Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:57 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Study Clear all
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Recruiting Phase 3 Interventional

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
riliprubart, Placebo, IVIg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

NCT00819052
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine XR, Nevirapine IR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Beverly Hills, California • Long Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study of Galcanezumab in Participants With Chronic Cluster Headache

NCT02438826
View directory record Official record
Conditions
Chronic Cluster Headache
Interventions
Galcanezumab 300 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Santa Monica, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Nov 1, 2026, 5:57 PM EST
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

NCT02295748
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
4 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 3 Interventional Results available

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

NCT02914600
View directory record Official record
Conditions
Crohn's Disease
Interventions
Filgotinib, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
100
States / cities
Dothan, Alabama • Sun City, Arizona • Coronado, California + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

PK and Safety After C-Section

NCT03955211
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, ZYNRELEF kit components for administration, MMA regimen
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Sheffield, Alabama • San Diego, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

NCT01280981
View directory record Official record
Conditions
Menorrhagia
Interventions
Tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

NCT00947544
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HPN-100, NaPBA
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

NCT04138277
View directory record Official record
Conditions
Pompe Disease (Late-onset)
Interventions
AT2221, ATB200
Drug · Biological
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

NCT01199614
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
open-label PTH(1-84)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study of Febuxostat XR in Healthy Participants

NCT02374164
View directory record Official record
Conditions
Gout
Interventions
Febuxostat XR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

NCT01224210
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 2 Interventional Results available

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 3 Interventional

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820
View directory record Official record
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions
INZ-701, Control Arm (Conventional Therapy)
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
1 Year to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Active, not recruiting Phase 2 Interventional

A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
AT02
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional

Pegcetacoplan Long Term Safety and Efficacy Extension Study

NCT03531255
View directory record Official record
Conditions
PNH
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 1, 2026, 5:57 PM EST
Withdrawn Phase 2 Interventional

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

NCT02429882
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Brodalumab 210 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

NCT02405780
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
FKB327, Humira®
Drug
Lead sponsor
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Peoria, Arizona • Palm Desert, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 1, 2026, 5:57 PM EST